NCATS 4DM · biologics

Biologics 4D Map

The Drug Discovery, Development and Deployment Map for biologics, drawn with monoclonal antibodies as the representative therapeutic. It lays out the modern therapeutic development process as eight connected neighborhoods rather than a straight line, so the dependencies that actually govern a program — and the bottlenecks between them — are visible in one view. Published by NCATS at the NIH and reproduced here under CC BY-SA 4.0.

What is specific to biologics

Six of the eight neighborhoods are common to both 4D Maps. Two are not — and they are the two that decide what a program actually looks like day to day: C, lead identification, and D, lead optimization. Two more, E and F, carry small but consequential biologics-only additions.

C · Lead identification is an immunology problem

Antigen presentation and immunization development feed library screening and assay development. What follows has no small-molecule counterpart at all: binding maturation, functional characterization, in silico immunological screening, and a delivery-device strategy that starts here rather than at formulation. The neighborhood exits with a candidate new biological entity (NBE) instead of a screened compound.

D · Lead optimization carries a manufacturing burden

Candidate optimization branches into CMC and biophysical characterization and into protein engineering. Non-GLP studies split between immunogenicity and toxicology models and PK/PD/efficacy models — immunogenicity is a first-class concern for a biologic, not a footnote. Early cGMP manufacturing arrives much earlier in the sequence than it does for a small molecule, and formulation is staged rather than settled once: Phase I formulation, then Phase II, then Phase III, with a device prototype and a qualified device tracked alongside. Any scale-up or process change forces a comparability exercise before the candidate can proceed to clinical studies.

E and F · the smaller divergences

Clinical development carries a combined regulatory-compliance and immunogenicity strategy where the small-molecule map carries compliance alone. Regulatory review runs to an NDA/BLA rather than an NDA, and exits to approved therapy or a Complete Response Letter.

The small-molecule map replaces C and D wholesale with high-throughput screening, medicinal and process chemistry, and long-term toxicology. Comparing the two side by side is the fastest way to see why a modality choice is a program-structure choice.

The shared neighborhoods

Substantively the same on both maps:

A · Basic science research & target identification — informatics, data mining and biorepositories, through pathophysiology, molecular pathways, cell lines and animal models, out to a therapeutic target.
B · Target pharmacology & biomarker development — target engagement, prognostic, predictive and response biomarkers, qualification, companion diagnostics and surrogate endpoints.
G · Postmarketing — postapproval data collection, spontaneous reporting, pragmatic safety and effectiveness trials, label changes, off-label use, and repurposing that feeds back into A.
H · Medical landscape — patient needs, standard of care, access to therapies, coverage and reimbursement, pricing, incorporation into practice.

Source and licence

The Drug Discovery, Development and Deployment Maps (4DM) are produced by the National Center for Advancing Translational Sciences at the National Institutes of Health, and are released under the Creative Commons Attribution-ShareAlike 4.0 International licence. This page reproduces the biologics map unchanged and is shared under the same licence. The current maps and the accompanying material are at ncats.nih.gov.

The maps are described in: Wagner JA, Dahlem AM, Hudson LD, Terry SF, Altman RB, Gilliland CL, DeFeo C, Austin CP. A dynamic map for learning, communicating, navigating and improving therapeutic development. Nature Reviews Drug Discovery 17, 150 (2017). doi:10.1038/nrd.2017.217

DISCLAIMER: Reference visualization for educational purposes only. Not legal, regulatory, or medical advice. Consult qualified professionals.